Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 0.51 |
| ▸ | CASP2 | P42575 | 1/20 | 0.51 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 2/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13063698 | 0.93 | CASP2 (0.56) | EPHX1CASP2NAAAMEN1ALDH1A1 | |
| SCHEMBL10046413 | 0.93 | EPHX1 (0.59) | EPHX1CASP2EPHX2 | |
| SCHEMBL10046349 | 0.93 | EPHX1 (0.59) | EPHX1CASP2EPHX2 | |
| SCHEMBL10046572 | 0.81 | GBA1 (0.44) | CASP2MEN1KMT2AFAAHGBA1 | |
| SCHEMBL13827121 | 0.79 | GBA1 (0.33) | EPHX1MEN1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL16473143 | 0.79 | EPHX1 (0.44) | EPHX1MEN1KMT2ASMN1; SMN2GBA1 | |
| SCHEMBL13019129 | 0.77 | EPHX1 (0.81) | EPHX1CASP2NAAAMEN1ALDH1A1 | |
| SCHEMBL8087339 | 0.76 | GBA1 (0.49) | CASP2NAAAMEN1ALDH1A1KMT2A | |
| SCHEMBL8508274 | 0.76 | EPHX1 (0.76) | EPHX1CASP2NAAAFAAHDNM1 | |
| SCHEMBL8088030 | 0.75 | GBA1 (0.50) | CASP2NAAAMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842626-B2 | Partially fluorinated compositions and surface active agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-11-30 | — | — | US | disclosed |
| US-20080113172-A1 | Partially fluorinated compositions and surface active agents | E. I. DU PONT DE NEMOURS AND COMPANY | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113172-A1 | Partially fluorinated compositions and surface active agents | FLNB, FLNA, FSCN1 | EPHX1 1467/4885CASP2 2101/4885NAAA 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.